INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms
Q4 2024 Management View CEO Raymond Tesi highlighted the transformative potential of 2024 for INmune Bio, emphasizing upcoming milestones. He noted the Phase 2 trial of XPro for Alzheimer's disease, ...
pharmaphorum21h
Chiesi backs growth plans with a €430m new plant in Italy
Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation. Read why KRYS ...
Polar plunge raises thousands for John Hudson Dilgen, Staten Islander with rare skin disease
Dilgen, a 22-year-old Tottenville resident, has been battling epidermolysis bullosa (EB), a rare, life-threatening genetic ...
What is HC Wainwright’s Estimate for ABEO Q1 Earnings?
Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Abeona Therapeutics in a research ...
Medscape5d
Epidermolysis Bullosa: The Challenges of Wound Care
Carol Schober-Flores, BSN, RN, is a Mohs Surgical Nurse and Epidermolysis Bullosa Nurse Specialist, University Hospital, Denver, CO. Topical ointments can be applied directly over the Mepitel ...
MetroWest Daily News7d
Wellesley will host 8th annual Plunge for Elodie to benefit Epidermolysis bullosa research
Wellesley will host the eighth annual Plunge for Elodie raises money to benefit research programs for Epidermolysis bullosa, a rare skin disease.
Dolphins Wire24d
Sam Schulz is the toughest person Chris Beard knows. Now he's inspiring Ole Miss basketball
Sam Schulz, a 20-year-old with Epidermolysis Bullosa, has developed a close friendship with Ole Miss basketball coach Chris Beard. Schulz, who is a big basketball fan, has become an inspiration to the ...